Skip to main content

UnitedHealth Group Faces New Challenges -- What Investors Need to Know

Motley Fool - Wed Feb 18, 10:35AM CST

Key Points

Last year was a difficult one for UnitedHealth Group(NYSE: UNH). The biggest health insurer in the U.S. came up against a number of headwinds -- from an ever-changing healthcare landscape to the unexpected exit of the company's chief executive officer and the launch of a government probe into its Medicare billing practices.

The company recognized its problems and took action. Longtime chief Stephen Hemsley returned to the role of CEO, the company launched an independent study into its processes, and UnitedHealth made moves to recover and reignite growth. All of this set the insurer off on the right foot heading into 2026.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »

But just recently, a new challenge emerged. Here's what investors need to know.

An investor works at a laptop and takes notes on a notepad.

Image source: Getty Images.

Rising costs of healthcare

First, though, let's take a quick look at UnitedHealth and its path in recent times. As mentioned, UnitedHealth's earnings growth has suffered due to the rising costs of healthcare, along with higher utilization than expected of certain services. But the company has recognized the problem and has taken steps such as cutting some plans, readjusting prices, and using AI to gain efficiency.

UnitedHealth operates UnitedHealthcare, its insurance arm, as well as Optum, its services unit. This business mix, as well as the company's insurance leadership in the U.S., offer it a significant moat, or competitive advantage. This is positive and should work to the company's favor over time once it meets growth goals in the coming years. UnitedHealth called this year one of "focus and execution" and predicts increasing momentum later in the year that should continue into 2027.

"Robust" processes

Meanwhile, UnitedHealth's study into its processes concluded that they were "robust," but offered suggestions for improvement to reinforce this strength. As for the U.S. probe, last year, UnitedHealth expressed confidence in its practices and said it would fully cooperate with the Justice Department.

So, it seems as if UnitedHealth is on the right track, making it a great recovery story to consider. But just recently, a new challenge emerged. The Trump administration proposed holding Medicare Advantage payment rates flat in 2027. These rates are key as they determine how much an insurer may charge for its services -- and therefore the profitability of the insurer. The proposal suggests increasing payment by 0.09% next year.

Centers for Medicare and Medicaid Services usually decides on the payment level by early April, so this suggestion hasn't yet become a reality. If it does, though, should investors worry? Of course, this isn't the brightest news for UnitedHealth and other health insurers. But it's important to remember that Medicare isn't UnitedHealth's only business -- it also generates revenue through insurance plans sold to employers. Finally, the Medicare payment decision for 2027 applies to that year only -- so a higher rate could be approved in the years to come.

All of this means the Medicare payment rate could be a headwind, but it doesn't change the company's potentially bright long-term prospects.

Should you buy stock in UnitedHealth Group right now?

Before you buy stock in UnitedHealth Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $415,256!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,133,904!*

Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of February 18, 2026.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.